
|Articles|April 27, 2012
AstraZeneca C.E.O. to Step Down
Advertisement
David Brennan, the chief executive of AstraZeneca, will step down on June 1 as the big British pharmaceutical company struggles with competition from makers of generic drugs and the failure of several drug development projects.
Mr. Brennan, 58, who has been in his post for six years, was under some pressure from shareholders to resign because of AstraZeneca’s performance.
Read the full story:
Source: The New York Times
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week
2
Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029
3
Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial
4
Impact of Automated Insulin Delivery on Type 2 Diabetes Measures
5




